还他妈第二天就人体实验？你知道上临床FDA多久可以批吗？
中共军方陈薇，2020/02/26新冠疫苗就已经投产下线
版主： Softfist
-
whoami（我是谁1）
- 见习点评
- 帖子： 1991
- 注册时间： 2022年 10月 30日 18:21
Re: 中共军方陈薇，2020/02/26新冠疫苗就已经投产下线
你造谣要有个度啊。这个过了。
还他妈第二天就人体实验？你知道上临床FDA多久可以批吗？
还他妈第二天就人体实验？你知道上临床FDA多久可以批吗？
-
ghobuster楼主
- 论坛精英
- 帖子： 5740
- 注册时间： 2022年 7月 31日 17:05
Re: 中共军方陈薇，2020/02/26新冠疫苗就已经投产下线
你就不要洗了。我问你一个最简单的问题，五毛们从来不敢正面回答。
新冠病毒到底是不是自然产生的？
新冠病毒到底是不是自然产生的？
Knifer 写了： 2022年 12月 17日 15:34 牛逼，还他妈的科研呢，川普都说了，we have a vaccine very early (something like that). 另外，摩德纳2017年就申请了相关专利，也是很牛逼的科研，哈哈哈
-
wanmeishijie（石昊）
- 论坛元老
wanmeishijie 的博客 - 帖子： 68580
- 注册时间： 2022年 12月 10日 23:58
Re: 中共军方陈薇，2020/02/26新冠疫苗就已经投产下线
她的技术传统，实验室出疫苗肯定很快。玄月给过解释。后来下线生产也快一年了
理解了老将是代入狗的视角之后，你就理解了老将
viewtopic.php?t=120513
理解了它们是代入狗的视角之后，它们为什么会嘲笑不愿意当狗的人，以及为什么会害怕想要反抗的人，就都可以理解了：
“放着好好的狗不当”
viewtopic.php?t=120513
理解了它们是代入狗的视角之后，它们为什么会嘲笑不愿意当狗的人，以及为什么会害怕想要反抗的人，就都可以理解了：
“放着好好的狗不当”
-
ghobuster楼主
- 论坛精英
- 帖子： 5740
- 注册时间： 2022年 7月 31日 17:05
Re: 中共军方陈薇，2020/02/26新冠疫苗就已经投产下线
2020.2.26，党国速度。
-
ghobuster楼主
- 论坛精英
- 帖子： 5740
- 注册时间： 2022年 7月 31日 17:05
-
kazan（喀山）
- 论坛支柱
- 帖子： 11484
- 注册时间： 2022年 10月 12日 18:39
Re: 中共军方陈薇，2020/02/26新冠疫苗就已经投产下线
2021年欧洲杯时有个五毛说，别的国家赛场都有限制，只有匈牙利用了中国疫苗赛场全开放 LOL
-
whoami（我是谁1）
- 见习点评
- 帖子： 1991
- 注册时间： 2022年 10月 30日 18:21
Re: 中共军方陈薇，2020/02/26新冠疫苗就已经投产下线
On January 11, 2020, the Chinese authorities shared the genetic sequence of the novel coronavirus.
On January 13, 2020, the U.S. National Institutes of Health (NIH) and Moderna’s infectious disease research team finalized the sequence for mRNA-1273, the Company’s vaccine against the novel coronavirus. At that time, the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, disclosed their intent to run a Phase 1 study using the mRNA-1273 vaccine in response to the coronavirus threat and Moderna mobilized toward clinical manufacture. Manufacture of this batch was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
On February 7, 2020, the first clinical batch, including fill and finishing of vials, was completed, a total of 25 days from sequence selection to vaccine manufacture. The batch then proceeded to analytical testing for release.
On February 24, 2020, the clinical batch was shipped from Moderna to the NIH for use in their Phase 1 clinical study.
On March 4, 2020, the U.S. Food and Drug Administration (FDA) completed its review of the Investigational New Drug (IND) application filed by the NIH for mRNA-1273 and allowed the study to proceed to begin clinical trials.
On March 16, 2020, the NIH announced that the first participant in its Phase 1 study for mRNA-1273 was dosed, a total of 63 days from sequence selection to first human dosing.
On January 13, 2020, the U.S. National Institutes of Health (NIH) and Moderna’s infectious disease research team finalized the sequence for mRNA-1273, the Company’s vaccine against the novel coronavirus. At that time, the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, disclosed their intent to run a Phase 1 study using the mRNA-1273 vaccine in response to the coronavirus threat and Moderna mobilized toward clinical manufacture. Manufacture of this batch was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
On February 7, 2020, the first clinical batch, including fill and finishing of vials, was completed, a total of 25 days from sequence selection to vaccine manufacture. The batch then proceeded to analytical testing for release.
On February 24, 2020, the clinical batch was shipped from Moderna to the NIH for use in their Phase 1 clinical study.
On March 4, 2020, the U.S. Food and Drug Administration (FDA) completed its review of the Investigational New Drug (IND) application filed by the NIH for mRNA-1273 and allowed the study to proceed to begin clinical trials.
On March 16, 2020, the NIH announced that the first participant in its Phase 1 study for mRNA-1273 was dosed, a total of 63 days from sequence selection to first human dosing.